Cytapheresis as a Non-Pharmacological Therapy for Inflammatory Bowel Disease

Publisher： Karger

E-ISSN： 1660-3818|35|1|18-23

ISSN： 1660-3796

Source： Transfusion Medicine and Hemotherapy, Vol.35, Iss.1, 2007-12, pp. : 18-23

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Selective Granulocyte and Monocyte Apheresis as a Non-Pharmacological Option for Patients with Inflammatory Bowel Disease

By  

Transfusion Medicine and Hemotherapy, Vol. 39, Iss. 4, 2012-07 ,pp. : 246-252

Karger

Access to resources Recommend Favorite

Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy

By Wan George J.   Kozma Chris M.   Slaton Terra L.   Olson William H.   Feagan Brian G.  

Journal of Medical Economics, Vol. 17, Iss. 6, 2014-06 ,pp. : 384-393

Informa Healthcare

Access to resources Recommend Favorite

Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease

By Mulder C. J. J.   Hazel S. J. Van Den  

Mediators of Inflammation, Vol. 7, Iss. 3, 1998-06 ,pp. : 135-136

Informa Healthcare

Access to resources Recommend Favorite

Letter: infliximab therapy for patients with inflammatory bowel disease – some unanswered questions

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 269-2813, Iss. 9, 2015-11 ,pp. : 1133-1133

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: infliximab therapy for patients with inflammatory bowel disease – some unanswered questions

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 9, 2015-11 ,pp. : 1133-1133

John Wiley & Sons Inc

Access to resources Recommend Favorite